Navigation Links
From surgery to laboratory and back again
Date:2/11/2014

A University of York scientist's experience in seeing his partner in hospital recovering from a double lung transplant prompted him to design and synthesise new chemical agents that could revolutionise post-operative patient care.

Professor Dave Smith, of the University's Department of Chemistry, led an international team which developed the agents that bind and potentially remove the anti-coagulant heparin.

Professor Smith says: 'I was sitting at my husband Sam's bedside while he recovered from a double lung transplant when the idea first came to me. I spent a long time talking to surgeons about all the drugs they used, and some of the problems they caused, and as I sat there, looking at all the tubes, I realised that perhaps my research team could help."

One of the drugs used during major surgery is heparin which helps to prevent the blood from clotting. Once the patient is in recovery, however, the surgeons want clotting to resume to aid the healing process. To do this they use a 'heparin rescue agent', called protamine, to remove heparin from the patient's bloodstream. But in some cases, this can cause side effects such as patients going into anaphylactic shock. As a result, doctors must use protamine cautiously, which can lead to inefficient clotting.

"I realised that my research group had developed expertise which could lead to chemical agents to bind, and perhaps remove the heparin. These chemical agents can be carefully designed to minimise side effects and so improve patient care," Professor Smith says.

He designs small drug-like molecules, which assemble spontaneously into larger nanostructures in order to bind the heparin using multivalent (many-bonds) interactions. In the latest research, published in Chemical Science, Professor Smith and his team, which includes researchers from University of Liverpool, University of Trieste, and Freie Universitt Berlin demonstrate that this approach works in vitro in human plasma, reversing the effect of heparin and allowing clotting to begin.

Importantly, the system is biodegradable unless bound to heparin, with the molecules slowly breaking down, leading to nanostructure disassembly and inactivation. This means that, in principle, plenty of this compound could be used, because any excess will be less likely to cause side effects.

Professor Smith adds: "This could revolutionise the way in which surgeons reverse the effects of heparin once surgery is complete. I call this 'self-assembled multivalent' approach to medicine as 'SAMul' nanomedicine in honour of Sam who gave me the initial inspiration."

The next stages of the research will involve further optimisation of the agents to maximise their binding and further minimise their toxicity prior to in vivo testing and eventual clinical trials.


'/>"/>

Contact: David Garner
david.garner@york.ac.uk
44-019-043-22153
University of York
Source:Eurekalert

Related biology news :

1. Gastric banding patients should closely monitor nutrition following surgery
2. Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find
3. Findings announced from landmark study on safety of adolescent bariatric surgery
4. Parkinsons Surgery Research wins NSF Grant
5. Breast cancer surgery linked to swollen arm syndrome
6. Chris Christie, Governor of New Jersey, Slims Down after Having Lap Band Surgery
7. Research shows Vitamin D levels drop after pediatric heart surgery, increasing sickness
8. Improved material for laser welding of tissue in intestinal surgery
9. Study finds possible alternative to bariatric weight loss surgery
10. What you eat before surgery may affect your recovery
11. Physical activity linked to lower rates of depression in bariatric surgery patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology: